Product Description
A drug used with other drugs to treat acute lymphoblastic leukemia in children and young adults aged 1 month to 21 years. It is also being studied in the treatment of other types of cancer. Calaspargase pegol is made up of the enzyme L-asparaginase that is linked to a substance called SC-PEG, which makes the drug stay in the body longer. L-asparaginase comes from the bacterium E. coli and breaks down the amino acid asparagine. This may stop the growth of cancer cells that need asparagine to grow. Calaspargase pegol is a type of protein synthesis inhibitor. Also called Asparlas, EZN-2285, and SC-PEG E. coli L-asparaginase. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/calaspargase-pegol)
Mechanisms of Action: L-Asparagine Converter
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: United States
Approved Indications: None
Known Adverse Events: None
Company: St. Jude Children's Research Hospital
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase 1: Adenocarcinoma|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| STUDY00022141 | P1 |
Active, not recruiting |
Adenocarcinoma|Pancreatic Cancer |
2025-12-16 |
50% |
2025-10-28 |
Primary Endpoints|Treatments|Trial Status |
| MCC-21213 | P1 |
Active, not recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2025-06-29 |
50% |
2025-08-13 |
Primary Completion Date|Primary Endpoints |
| SJALL23H | P2 |
Recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2028-05-01 |
2% |
2025-01-11 |
|
| TOT17 | P3 |
Active, not recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2026-09-30 |
27% |
2024-11-27 |
Primary Endpoints|Treatments |